Chris A. Rallis - 10 Oct 2025 Form 4 Insider Report for FENNEC PHARMACEUTICALS INC. (FENC)

Role
Director
Signature
/s/ Chris Rallis
Issuer symbol
FENC
Transactions as of
10 Oct 2025
Net transactions value
-$16,401
Form type
4
Filing time
14 Oct 2025, 16:10:05 UTC
Previous filing
07 Jul 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
RALLIS CHRIS A Director C/O FENNEC PHARMACEUTICALS, INC., PO BOX 13628, 68 TW ALEXANDER DRIVE, RESEARCH TRIANGLE PARK /s/ Chris Rallis 14 Oct 2025 0001185945

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FENC Common Shares Options Exercise $4,996 +4,062 +7.4% $1.23 58,854 10 Oct 2025 Direct F1
transaction FENC Common Shares Sale $16,401 -1,775 -3% $9.24 57,079 10 Oct 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FENC Common Shares Options Exercise $4,996 -4,062 -2.3% $1.23 174,344 10 Oct 2025 Options 4,062 $1.23 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on May 19, 2025.
F2 Shares sold to satisfy tax obligation on option exercise.
F3 Represents options exercised pursuant to a 10b5-1 plan adopted on May 19, 2025.